Generic placeholder image

Current Cancer Therapy Reviews

Editor-in-Chief

ISSN (Print): 1573-3947
ISSN (Online): 1875-6301

Review Article

Recent Advancements for the Management of Pancreatic Cancer: Current Insights

Author(s): Naureen Ali and Nimisha Srivastava*

Volume 17 , Issue 4 , 2021

Published on: 25 June, 2021

Page: [267 - 282] Pages: 16

DOI: 10.2174/1573394717666210625153256

Price: $65

Abstract

One of the most fatal forms of cancer includes cancer of the pancreas And the most rapid malignancy is observed in PDAC (pancreatic ductal adenocarcinoma). The high lethality rate is generally due to very late diagnosis and resistance to traditional chemotherapeutic agents. Desmoplastic stromal barrier results in resistance to immunotherapy. Other reasons for the high lethality rate include the absence of effective treatment and standard screening tests. Hence, there is a need for effective novel carrier systems. “A formulation, method, or device that allows the desired therapeutic substance to reach its site of action in such a manner that nontarget cells experience minimum effect is referred to as a drug delivery system”. The delivery system is responsible for introducing the active component into the body. They are also liable for boosting the efficacy and desirable targeted action on the tumorous tissues. Several studies, researches, and developments have yielded various advanced drug delivery systems, which include liposomes, nanoparticles, carbon nanotubules, renovoCath, etc. These systems control rate and location of the release. They are designed while taking into consideration characteristic properties of the tumor and tumor stroma. These delivery systems overcome the barriers in drug deliverance in pancreatic cancer. Alongside providing palliative benefits, these delivery systems also aim to correct the underlying reason for the defect. The following review article aims and focuses to bring out a brief idea about systems, methods, and technologies for futuristic drug deliverance in pancreatic cancer therapy.

Keywords: Pancreatic cancer, pancreatic ductal adenocarcinoma (PDAC), liposomes, nanoparticles, carbon nanotubules, Single-Walled Carbon Nanotubules (SWCNT), Multi-Walled Carbon Nanotubules (MWCNT), renovoCath.

Graphical Abstract
[1]
Zhang Q, Zeng L, Chen Y, et al. Pancreatic cancer epidemiology, detection, and management. Gastroenterol Res Pract 2016; 2016: 8962321.
[http://dx.doi.org/10.1155/2016/8962321] [PMID: 26941789]
[2]
Tseng JF, Mulligan RC. Gene therapy for pancreatic cancer. Surg Oncol Clin N Am 2002; 11(3): 537-69.
[http://dx.doi.org/10.1016/S1055-3207(02)00023-6] [PMID: 12487056]
[3]
Pereira NP, Corrêa JR. Pancreatic cancer: Treatment approaches and trends. J Cancer Metastasis Treat 2018; 4 Available from:. https://jcmtjournal.com/article/view/2628 [Cited 2020 Dec 23].
[4]
Oberstein PE, Olive KP. Pancreatic cancer: Why is it so hard to treat? Therap Adv Gastroenterol 2013; 6(4): 321-37.
[http://dx.doi.org/10.1177/1756283X13478680] [PMID: 23814611]
[5]
Malaiya A, Jain D, Yadav AK. Chapter 6 - nanoparticles and pancreas cancer. Nano drug delivery strategies for the treatment of cancers. USA Academic press 2021; pp. 145-64; Available from:. http://www.sciencedirect.com/science/article/pii/B9780128197936000072 [Cited 2020 Dec 19].
[6]
Ren B, Liu X, Suriawinata AA. Pancreatic ductal adenocarcinoma and its precursor lesions: Histopathology, cytopathology, and molecular pathology. Am J Pathol 2019; 189(1): 9-21.
[http://dx.doi.org/10.1016/j.ajpath.2018.10.004] [PMID: 30558727]
[7]
Bellizzi AM, Frankel WL. Pancreatic pathology: A practical review. Lab Med 2009; 40(7): 417-26.
[http://dx.doi.org/10.1309/LM5MY3OCDWWKS6NM]
[9]
Types of pancreatic cancer Available from: . https://hillman.upmc.com/cancer-care/pancreatic/types [Cited 2020 Dec 20].
[10]
Hruban RH, Gaida MM, Thompson E, et al. Why is pancreatic cancer so deadly? The pathologist’s view. J Pathol 2019; 248(2): 131-41.
[http://dx.doi.org/10.1002/path.5260] [PMID: 30838636]
[11]
Su T, Yang B, Gao T, Liu T, Li J. Polymer nanoparticle-assisted chemotherapy of pancreatic cancer. Ther Adv Med Oncol 2020; 12: 1758835920915978.
[http://dx.doi.org/10.1177/1758835920915978] [PMID: 32426046]
[12]
McCarroll J, Teo J, Boyer C, Goldstein D, Kavallaris M, Phillips P. Potential applications of nanotechnology for the diagnosis and treatment of pancreatic cancer. Front Physiol 2014; 5 Available from:. https://www.frontiersin.org/articles/10.3389/fphys.2014.000 02/full [Cited 2020 Dec 19].
[http://dx.doi.org/10.3389/fphys.2014.00002]
[13]
Yu X, Zhang Y, Chen C, Yao Q, Li M. Targeted drug delivery in pancreatic cancer. Biochim Biophys Acta 2010; 1805(1): 97-104.
[14]
Pancreatic cancer: Overview. Cancer council victoria Available from:. https://www.cancervic.org.au/cancer-information/types-of- cancer/pancreatic_cancer/pancreatic-cancer-overview.html [Cited 2020 Nov 7].
[15]
Aslan M, Shahbazi R, Ulubayram K, Ozpolat B. Targeted therapies for pancreatic cancer and hurdles ahead. Anticancer Res 2018; 38(12): 6591-606.
[http://dx.doi.org/10.21873/anticanres.13026] [PMID: 30504367]
[16]
Furukawa T. Molecular pathology of pancreatic cancer: Implications for molecular targeting therapy. Clin Gastroenterol Hepatol 2009; 7(11)(Suppl.): S35-9.
[http://dx.doi.org/10.1016/j.cgh.2009.07.035] [PMID: 19896096]
[17]
Ying H, Dey P, Yao W, et al. Genetics and biology of pancreatic ductal adenocarcinoma. Genes Dev 2016; 30(4): 355-85.
[http://dx.doi.org/10.1101/gad.275776.115] [PMID: 26883357]
[18]
Li D, Xie K, Wolff R, Abbruzzese JL. Pancreatic cancer. Lancet 2004; 363(9414): 1049-57.
[http://dx.doi.org/10.1016/S0140-6736(04)15841-8] [PMID: 15051286]
[19]
Li Z, Li W, Sun YD, X. Novel molecular targets and mechanisms involved in the invasion and metastasis of pancreatic cancer. Clinical Cancer Drugs 2019; 6: 8-20. Internet Available from:. https://www.eurekaselect.com/171082/article [Cited 2020 Dec 20].
[20]
Zamboni G, Capelli P, Pesci A, Beghelli S, Lüttges J, Klöppel G. Pancreatic head mass: What can be done? Classification: The pathological point of view. JOP 2000; 1(3 Suppl): 77-84. Available from:. https://pancreas.imedpub.com/pancreatic-head-mass- what-can-be-done-classification-the-pathological-point-of-view.php?aid=3013 [Cited 2020 Dec 20].
[21]
All about pancreatic cancer. OncoLink Available from:. https://www.oncolink.org/cancers/gastrointestinal/pancreatic- cancer/all-about-pancreatic-cancer [Cited 2020 Nov 7].
[22]
Pancreatic cancer - stages. CancerNet 2012. Available from: https://www.cancer.net/cancer-types/pancreatic-cancer/stages [Cited 2020 Dec 20].
[23]
Pancreatic cancer | pathology. Encyclopedia britannica Available from: https://www.britannica.com/science/pancreatic-cancer [Cited 2020 Dec 20].
[24]
Pancreatic cancer | Causes, symptoms & treatments. Available from: https://www.cancer.org.au/cancer-information/types-of-cancer/pancreatic-cancer [Cited 2020 Dec 20].
[25]
Pancreatic cancer: Signs, symptoms, stages & treatment. Narayana health Available from: https://www.narayanahealth.org/pancreatic-cancer/ [Cited 2020 Dec 20].
[26]
Yabar CS, Winter JM. Pancreatic cancer. Gastroenterol Clin North Am 2016; 45(3): 429-45.
[http://dx.doi.org/10.1016/j.gtc.2016.04.003] [PMID: 27546841]
[27]
Chu LC, Goggins MG, Fishman EK. Diagnosis and detection of pancreatic cancer. Cancer J 2017; 23(6): 333-42.
[http://dx.doi.org/10.1097/PPO.0000000000000290] [PMID: 29189329]
[28]
Risk factors for pancreas cancer. Available from: https://pathology.jhu.edu/pancreas/BasicRisk.php?area=ba [Cited 2020 Dec 19].
[29]
McGuigan A, Kelly P, Turkington RC, Jones C, Coleman HG, McCain RS. Pancreatic cancer: A review of clinical diagnosis, epidemiology, treatment and outcomes. World J Gastroenterol 2018; 24(43): 4846-61.
[http://dx.doi.org/10.3748/wjg.v24.i43.4846] [PMID: 30487695]
[30]
Pancreatic cancer - risk factors. CancerNet 2012. Available from: https://www.cancer.net/cancer-types/pancreatic-cancer/risk-factors [Cited 2020 Dec 20].
[31]
Pancreatic cancer risk factors Available from: https://www.cancer.org/cancer/pancreatic-cancer/causes-risks-prevention/risk-factors.html [Cited 2020 Dec 19].
[32]
Pancreatic cancer risk factors Available from: https://www.cancer.org/cancer/pancreatic-cancer/causes-risks-prevention/risk-factors.html [Cited 2020 Dec 19].
[33]
Lei F, Xi X, Batra SK, Bronich TK. Combination therapies and drug delivery platforms in combating pancreatic cancer. J Pharmacol Exp Ther 2019; 370(3): 682-94.
[http://dx.doi.org/10.1124/jpet.118.255786] [PMID: 30796131]
[34]
Swayden M, Iovanna J, Soubeyran P. Pancreatic cancer chemo-resistance is driven by tumor phenotype rather than tumor genotype. Heliyon 2018; 4(12): e01055.
[http://dx.doi.org/10.1016/j.heliyon.2018.e01055] [PMID: 30582059]
[35]
Novel treatment strategies are explored in pancreatic cancer. Targeted oncology Available from: https://www.targetedonc.com/view/novel-treatment-strategies-are-explored-in-pancreatic-cancer [Cited 2020 Dec 20].
[36]
Ottenhof NA, de Wilde RF, Maitra A, Hruban RH, Offerhaus GJA. Molecular characteristics of pancreatic ductal adenocarcinoma. Pathol Res Int 2011; 2011: 620601.
[http://dx.doi.org/10.4061/2011/620601] [PMID: 21512581]
[37]
Wang H, Pei W, Luan Q, et al. A feasibility study on gene therapy of pancreatic carcinoma with Ad-PUMA. Cancer Biol Ther 2012; 13(9): 712-9.
[http://dx.doi.org/10.4161/cbt.20552] [PMID: 22617775]
[38]
Looi C-K, Chung FF-L, Leong C-O, Wong S-F, Rosli R, Mai C-W. Therapeutic challenges and current immunomodulatory strategies in targeting the immunosuppressive pancreatic tumor microenvironment. J Exp Clin Cancer Res 2019; 38(1: 162)
[http://dx.doi.org/10.1186/s13046-019-1153-8] [PMID: 30987642]
[39]
Sawant RR, Torchilin VP. Challenges in development of targeted liposomal therapeutics. AAPS J 2012; 14(2): 303-15.
[http://dx.doi.org/10.1208/s12248-012-9330-0] [PMID: 22415612]
[40]
Shi Y, van der Meel R, Chen X, Lammers T. The EPR effect and beyond: Strategies to improve tumor targeting and cancer nanomedicine treatment efficacy. Theranostics 2020; 10(17): 7921-4.
[http://dx.doi.org/10.7150/thno.49577] [PMID: 32685029]
[41]
Dimou A, Syrigos KN, Saif MW. Overcoming the stromal barrier: Technologies to optimize drug delivery in pancreatic cancer. Ther Adv Med Oncol 2012; 4(5): 271-9.
[http://dx.doi.org/10.1177/1758834012446008] [PMID: 22942909]
[42]
Golombek SK, May J-N, Theek B, et al. Tumor targeting via EPR: Strategies to enhance patient responses. Adv Drug Deliv Rev 2018; 130: 17-38.
[http://dx.doi.org/10.1016/j.addr.2018.07.007] [PMID: 30009886]
[43]
Tanaka HY, Kano MR. Stromal barriers to nanomedicine penetration in the pancreatic tumor microenvironment. Cancer Sci 2018; 109(7): 2085-92.
[http://dx.doi.org/10.1111/cas.13630] [PMID: 29737600]
[44]
Liu X, Jiang J, Meng H. Transcytosis - An effective targeting strategy that is complementary to “EPR effect” for pancreatic cancer nano drug delivery. Theranostics 2019; 9(26): 8018-25.
[http://dx.doi.org/10.7150/thno.38587] [PMID: 31754378]
[45]
Lamichhane N, Udayakumar TS, D’Souza WD, et al. Liposomes: Clinical applications and potential for image-guided drug delivery. Molecules 2018; 23(2): 288.
[http://dx.doi.org/10.3390/molecules23020288] [PMID: 29385755]
[46]
de Arajo Lopes SC, dos Santos Giuberti C, Ribeiro TG, dos Santos Ferreira D, Amaral Leite E, Cristina M. Liposomes as carriers of anticancer drugs.Cancer treatment - conventional and innovative approaches. 2013. Available from: http://www.intechopen.com/books/cancer-treatment-conventional-and-innovative-approaches/liposomes-as-carriers-of-anticancer-drugs [Cited 2020 Oct 21].
[http://dx.doi.org/10.5772/55290]
[47]
Liposome as a carrier for advanced drug delivery. Science alert Available from: https://scialert.net/fulltext/?doi=pjbs.2006.1181.1191 [Cited 2020 Dec 23].
[48]
Yang F, Jin C, Jiang Y, et al. Liposome based delivery systems in pancreatic cancer treatment: From bench to bedside. Cancer Treat Rev 2011; 37(8): 633-42.
[http://dx.doi.org/10.1016/j.ctrv.2011.01.006] [PMID: 21330062]
[49]
Yan W, Leung SS, To KK. Updates on the use of liposomes for active tumor targeting in cancer therapy. Nanomedicine (Lond) 2020; 15(3): 303-18.
[http://dx.doi.org/10.2217/nnm-2019-0308] [PMID: 31802702]
[50]
Alavi M, Karimi N, Safaei M. Application of various types of liposomes in drug delivery systems. Adv Pharm Bull 2017; 7(1): 3-9.
[http://dx.doi.org/10.15171/apb.2017.002] [PMID: 28507932]
[51]
Sheoran R, Khokra SL, Dureja VC, H. Recent patents, formulation techniques, classification and characterization of liposomes. Recent Patents Nanotechnol 2019; 13: 17-27. Available from: https://www.eurekaselect.com/167764/article [Cited 2020 Dec 19].
[52]
Jurj A, Braicu C, Pop L-A, Tomuleasa C, Gherman CD, Berindan-Neagoe I. The new era of nanotechnology, an alternative to change cancer treatment. Drug Des Develop Ther 2017; 11: 2871-90.
[53]
Jain* AJ, SK. Advances in tumor targeted liposomes. Curr Mol Med 2017; 18: 44-57. Available from: https://www.eurekaselect.com/161284/article [Cited 2020 Dec 20].
[54]
Jani RK, Gohil KM. Liposomal formulations in cancer therapy: Basic concepts to advanced strategies. Int J Pharm Sci Drug Res 2018; 10(05): 386-93.
[55]
Bulbake U, Doppalapudi S, Kommineni N, Khan W. Liposomal formulations in clinical use: An updated review. Pharmaceutics 2017; 9(2): 12.
[http://dx.doi.org/10.3390/pharmaceutics9020012] [PMID: 28346375]
[56]
Fan Y, Zhang Q. Development of liposomal formulations: From concept to clinical investigations. Asian J Pharm Sci 2013; 8(2): 81-7.
[http://dx.doi.org/10.1016/j.ajps.2013.07.010]
[57]
Stathopoulos GP, Boulikas T, Vougiouka M, Rigatos SK, Stathopoulos JG. Liposomal cisplatin (Lipoplatin) in combination with gemcitabine for pancreatic cancer – first line. Oncol Rep 2006; 15(5): 1201-4.
[58]
Dang S-C, Malik A, Wei J, et al. Liposomes and nanotechnology in drug development: Focus on pancreatic cancer. J Gastroenterol Pancreatol Liver Disord 2017; 4(5): 1-10.
[http://dx.doi.org/10.15226/2374-815X/4/5/00197]
[59]
Daraee H, Etemadi A, Kouhi M, Alimirzalu S, Akbarzadeh A. Application of liposomes in medicine and drug delivery. Artif Cells Nanomed Biotechnol 2016; 44(1): 381-91.
[http://dx.doi.org/10.3109/21691401.2014.953633] [PMID: 25222036]
[60]
Lee M-K. Liposomes for enhanced bioavailability of water-insoluble drugs: In vivo evidence and recent approaches. Pharmaceutics 2020; 12(3): 264.
[http://dx.doi.org/10.3390/pharmaceutics12030264] [PMID: 32183185]
[61]
Yadav D, Sandeep K, Pandey D, Dutta RK. Liposomes for drug delivery. J Biotechnol Biomater 2017; 07(04): 276.
[62]
Kalepu VN, S. Liposomal drug delivery: A review. Pharmaceut Nanotechnol 2015; 3: pp.: 35-55. Available from: https://www.eurekaselect.com/132971/article [Cited 2020 Dec 20].
[63]
Pandey H, Rani R, Agarwal V. Sam Higginbottom Institute of Agriculture Technology & Sciences, India, Motilal Nehru National Institute of Technology, India.. Liposome and their applications in cancer therapy. Braz arch biol technol 2016; 59: 1. Available from: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S15 16-89132016000100303&lng=en&tlng=en [Cited 2020 Oct 21].
[64]
Khan YY, Suvarna V. Liposomes containing phytochemicals for cancer treatment-an update. Int J Curr Pharm Res 2016; 9(1): 20.
[http://dx.doi.org/10.22159/ijcpr.2017v9i1.16629]
[65]
Beltrán-Gracia E, López-Camacho A, Higuera-Ciapara I, Velázquez-Fernández JB, Vallejo-Cardona AA. Nanomedicine review: Clinical developments in liposomal applications. Cancer Nanotechnol 2019; 10(1): 11.
[http://dx.doi.org/10.1186/s12645-019-0055-y]
[66]
Wu H, Yu M, Miao Y, et al. Cholesterol-tuned liposomal membrane rigidity directs tumor penetration and anti-tumor effect. Acta Pharm Sin B 2019; 9(4): 858-70.
[http://dx.doi.org/10.1016/j.apsb.2019.02.010] [PMID: 31384544]
[67]
Olusanya TOB, Haj Ahmad RR, Ibegbu DM, Smith JR, Elkordy AA. Liposomal drug delivery systems and anticancer drugs. Molecules 2018; 23(4): 907.
[http://dx.doi.org/10.3390/molecules23040907] [PMID: 29662019]
[68]
Frampton JE. Liposomal irinotecan: A review in metastatic pancreatic adenocarcinoma. Drugs 2020; 80(10): 1007-18.
[http://dx.doi.org/10.1007/s40265-020-01336-6] [PMID: 32557396]
[69]
Woo W, Carey ET, Choi M. Spotlight on liposomal irinotecan for metastatic pancreatic cancer: Patient selection and perspectives. OncoTargets Ther 2019; 12: 1455-63.
[http://dx.doi.org/10.2147/OTT.S167590] [PMID: 30863113]
[70]
Das M, Huang L. Liposomal nanostructures for drug delivery in gastrointestinal cancers. J Pharmacol Exp Ther 2019; 370(3): 647-56.
[http://dx.doi.org/10.1124/jpet.118.254797] [PMID: 30541917]
[71]
Macarulla Mercadé T, Chen L-T, Li C-P, et al. Liposomal irinotecan + 5-fu/lv in metastatic pancreatic cancer: Subgroup analyses of patient, tumor, and previous treatment characteristics in the pivotal napoli-1 trial. Pancreas 2020; 49(1): 62-75.
[http://dx.doi.org/10.1097/MPA.0000000000001455] [PMID: 31856081]
[72]
Ji T, Lang J, Wang J, et al. Designing liposomes to suppress extracellular matrix expression to enhance drug penetration and pancreatic tumor therapy. ACS Nano 2017; 11(9): 8668-78.
[http://dx.doi.org/10.1021/acsnano.7b01026] [PMID: 28806504]
[73]
Passero FC Jr, Grapsa D, Syrigos KN, Saif MW. The safety and efficacy of Onivyde (irinotecan liposome injection) for the treatment of metastatic pancreatic cancer following gemcitabine-based therapy. Expert Rev Anticancer Ther 2016; 16(7): 697-703.
[http://dx.doi.org/10.1080/14737140.2016.1192471] [PMID: 27219482]
[74]
Wang-Gillam A, Hubner RA, Siveke JT, et al. NAPOLI-1 phase 3 study of liposomal irinotecan in metastatic pancreatic cancer: Final overall survival analysis and characteristics of long-term survivors. Eur J Cancer 2019; 108: 78-87.
[http://dx.doi.org/10.1016/j.ejca.2018.12.007] [PMID: 30654298]
[75]
Lisa A, Raedler P. Onivyde (irinotecan liposome injection) a new treatment option for patients with metastatic pancreatic cancer 2016. Available from: http://www.ahdbonline.com/issues/2016/march-2016-vol-9-seventh-annual-payers-guide/2138-onivyde-irinotecan-liposome-injection-a-new-treatment-option-for-patients-with-metastatic-pancreatic-cancer2 [Cited 2020 Dec 20].
[76]
Palchetti S, Caputo D, Digiacomo L, et al. Protein corona fingerprints of liposomes: New opportunities for targeted drug delivery and early detection in pancreatic cancer. Pharmaceutics 2019; 11(1): 31.
[http://dx.doi.org/10.3390/pharmaceutics11010031] [PMID: 30650541]
[77]
Cancer nanotechnology Available from: https://cancer-nano.biomedcentral.com/pancreatic-cancer [Cited 2020 Dec 20].
[78]
Yang F, Jin C, Subedi S, et al. Emerging inorganic nanomaterials for pancreatic cancer diagnosis and treatment. Cancer Treat Rev 2012; 38(6): 566-79.
[http://dx.doi.org/10.1016/j.ctrv.2012.02.003] [PMID: 22655679]
[79]
He X, Chen X, Liu L, et al. Sequentially triggered nanoparticles with tumor penetration and intelligent drug release for pancreatic cancer therapy. Adv Sci (Weinh) 2018; 5(5): 1701070.
[http://dx.doi.org/10.1002/advs.201701070] [PMID: 29876225]
[80]
Giordano G, Pancione M, Olivieri N, et al. Nano albumin bound-paclitaxel in pancreatic cancer: Current evidences and future directions. World J Gastroenterol 2017; 23(32): 5875-86.
[http://dx.doi.org/10.3748/wjg.v23.i32.5875] [PMID: 28932079]
[81]
Din F ud, Aman W Ullah I, Qureshi OS, Mustapha O, Shafique S. Effective use of nanocarriers as drug delivery systems for the treatment of selected tumors. International journal of nanomedicine. Dove Press 2017; 12: pp. 7291-309.
[82]
Rebelo A, Reis C. Emerging therapeutic nanotechnologies in pancreatic cancer: Advances, risks and challenges. Ther Deliv 2018; 9(10): 691-4.
[http://dx.doi.org/10.4155/tde-2018-0048] [PMID: 30277137]
[83]
Brachi G, Bussolino F, Ciardelli G, Mattu C. Nanomedicine for imaging and therapy of pancreatic adenocarcinoma. Front Bioeng Biotechnol 2019; 7: 307.
[http://dx.doi.org/10.3389/fbioe.2019.00307] [PMID: 31824928]
[84]
Qiao W, Wang B, Wang Y, Yang L, Zhang Y, Shao P. Cancer therapy based on nanomaterials and nanocarrier systems. J Nanomater 2010; 2010: 1-9.
[http://dx.doi.org/10.1155/2010/796303]
[85]
Wang J, He Z-W, Jiang J-X. Nanomaterials: Applications in the diagnosis and treatment of pancreatic cancer. World J Gastrointest Pharmacol Ther 2020; 11(1): 1-7.
[http://dx.doi.org/10.4292/wjgpt.v11.i1.1] [PMID: 32405438]
[86]
Patra CR, Bhattacharya R, Mukhopadhyay D, Mukherjee P. Fabrication of gold nanoparticles for targeted therapy in pancreatic cancer. Adv Drug Deliv Rev 2010; 62(3): 346-61.
[http://dx.doi.org/10.1016/j.addr.2009.11.007] [PMID: 19914317]
[87]
Rastogi V, Yadav P, Bhattacharya SS, et al. Carbon nanotubes: An emerging drug carrier for targeting cancer cells. J Drug Deliver 2014; e670815.
[88]
Eatemadi A, Daraee H, Karimkhanloo H, et al. Carbon nanotubes: Properties, synthesis, purification, and medical applications. Nanoscale Res Lett 2014; 9(1): 393.
[http://dx.doi.org/10.1186/1556-276X-9-393] [PMID: 25170330]
[89]
Ribeiro B, Botelho EC, Costa ML, Bandeira CF. Carbon nanotube buckypaper reinforced polymer composites: A review. Polímeros 2017; 27(3): 247-55.
[http://dx.doi.org/10.1590/0104-1428.03916]
[90]
Harik V. Nanotechnology of carbon nanotubes. Mechanics of carbon nanotubes Elsevier 2018; pp. 1-24..
[91]
Singh R, Mehra NK, Jain V, Jain NK. Gemcitabine-loaded smart carbon nanotubes for effective targeting to cancer cells. J Drug Target 21(6): 581-92.
[92]
Short nanotubes target pancreatic cancer. ScienceDaily Available from: https://www.sciencedaily.com/releases/2014/06/140605 155 810.htm [Cited 2020 Dec 9].
[93]
Bhushan A, Desai V, Lai JCK, Leung S, Zhang Y. Cytotoxic effects of short multi-wall carbon nanotubes on pancreatic cancer cells. Techconnect Briefs 2019; (2019): 397-400.
[94]
Stopa KB, Kusiak AA, Szopa MD, Ferdek PE, Jakubowska MA. Pancreatic cancer and its microenvironment-recent advances and current controversies. Int J Mol Sci 2020; 21(9): 3218.
[http://dx.doi.org/10.3390/ijms21093218] [PMID: 32370075]
[95]
Layton E, McNamar R, Hasanjee AM, McNair C, Stevens B, Vaughan M. The effects of single-walled carbon nanotubes on cancer cell migration using a pancreatic tumor model. Biophotonics and immune responses XII. Int Soc Optics Photon 2017; 2017: 100650Z.
[96]
Lahiani MH, Eassa S, Parnell C, et al. Carbon nanotubes as carriers of Panax ginseng metabolites and enhancers of ginsenosides Rb1 and Rg1 anti-cancer activity. Nanotechnology 2017; 28(1): 015101.
[http://dx.doi.org/10.1088/0957-4484/28/1/015101] [PMID: 27893436]
[97]
Wang Z, Tao J, Liu JC, Q. Carbon nanotubes enhance the chemotherapy sensitivity of tumors with multidrug resistance 2020; 17: 366-78. Internet]. Available from: https://www.eurekaselect.com/171311/article [Cited 2020 Nov 7].
[98]
RenovoRx – developing innovative solutions for targeted delivery. RenovoRx Available from: https://renovorx.com/ [Cited 2020 Dec 23].
[99]
A multi-center, post-marketing, prospective, observational study following treatment with intra-arterial delivery of chemotherapeutic agents using the renovocathtm rc120 catheter 2020. Available from: https://clinicaltrials.gov/ct2/show/NCT02591082 [Cited 2020 Oct 26].
[100]
Renovorx announces $10 million financing for innovative treatment for advanced pancreatic cancer. 2018. Available from: https://www.businesswire.com/news/home/20180523005383/en/RenovoRx-Announces-10-Million-Financing-for-Innovative-Treatment-for-Advanced-Pancreatic-Cancer [Cited 2020 Dec 9].
[101]
Innovative drug delivery system shows promise in advanced pancreatic cancer treatment Available from: https://myacare.com/en/mya-blog/innovative-drug-delivery-system-shows-prom ise-in-advanced-pancreatic-cancer-treatment [Cited 2020 Oct 27].
[102]
RenovoRx announces fda clearance for expanded labeling. RenovoRx 2017. Available from: https://renovorx.com/renovorx-announces-fda-clearance-expanded-labeling/ [Cited 2020 Dec 23].
[103]
Intra-arterial treatment of pancreatic cancer using the renovocathtm rc120 catheter Available from: https://www.smartpatients.com/trials/NCT02591082 [Cited 2020 Oct 27].
[104]
RenovoRx release: Researchers report survival benefits with use of renovocath in patients with locally advanced pancreatic tumors. BioSpace Available from: https://www.biospace.com/article/renovorx-release-researchers-report-survival-benefits-with-use-of-renovocath-in-patients-with-locally-advanced-pancreatic-tumors-/ [Cited 2020 Oct 27].
[105]
RenovoRx. RenovoCathTM RC120 catheter receives fda clearance Available from: https://www.prnewswire.com/news-releases/renovocath-rc120-catheter-receives-fda-clearance-280929472. html [Cited 2020 Dec 23].
[106]
Kurtanich T, Roos N, Wang G, Yang J, Wang A, Chung EJ. Pancreatic cancer gene therapy delivered by nanoparticles. SLAS Technol 2019; 24(2): 151-60.
[http://dx.doi.org/10.1177/2472630318811108] [PMID: 30395768]
[107]
Bhattacharyya M, Lemoine NR. Gene therapy developments for pancreatic cancer. Best Pract Res Clin Gastroenterol 2006; 20(2): 285-98.
[http://dx.doi.org/10.1016/j.bpg.2005.10.004] [PMID: 16549328]
[108]
Li W, Satoh K, Li DGL, M. MicroRNAs and pancreatic cancer: Current research and future outlooks. Curr Signal Transduc Ther 2012; 7: 305-7. Available from: https://www.eurekaselect.com/102033/article [Cited 2020 Dec 20].
[109]
Liu S-X, Xia ZS, Zhong YQ. Gene therapy in pancreatic cancer. World J Gastroenterol 2014; 20(37): 13343-68.
[http://dx.doi.org/10.3748/wjg.v20.i37.13343] [PMID: 25309069]
[110]
Khan S, Chauhan N, Yallapu MM, Ebeling MC, Ellis RT, Thompson PA. Nanoparticle formulation of ormeloxifene for pancreatic cancer. Biomaterials 2015; 53: 731-43.
[111]
Shetty A, Nagesh PKB, Setua S, et al. Novel paclitaxel nanoformulation impairs de novo lipid synthesis in pancreatic cancer cells and enhances gemcitabine efficacy. ACS Omega 2020; 5(15): 8982-91.
[http://dx.doi.org/10.1021/acsomega.0c00793] [PMID: 32337462]
[112]
Yallapu MM, Ebeling MC, Khan S, et al. Novel curcumin-loaded magnetic nanoparticles for pancreatic cancer treatment. Mol Cancer Ther 2013; 12(8): 1471-80.
[http://dx.doi.org/10.1158/1535-7163.MCT-12-1227] [PMID: 23704793]
[113]
PRIME PubMed. Novel curcumin-loaded magnetic nanoparticles for pancreatic cancer treatment Available from: https://www.unboundmedicine.com/medline/citation/23704793/Novel_curcumin_loaded_magnetic_nanoparticles_for_pancreatic_cancer_treatment_ [Cited 2020 Dec 20].
[114]
Restricted research public Available from: www.highered.texas. gov/apps/restrictedresearchpublic/ [Cited 2020 Dec 20].
[115]
Cheng T. Topically applicated curcumin/gelatin-blended nanofibrous mat inhibits pancreatic adenocarcinoma by increasing ROS production and endoplasmic reticulum stress mediated apoptosis. J Nanobiotechnol 18(1): 126.
[116]
Sercombe L, Veerati T, Moheimani F, Wu SY, Sood AK, Hua S. Advances and challenges of liposome assisted drug delivery. Front Pharmacol 2015; 2015: 6.
[http://dx.doi.org/10.3389/fphar.2015.00286]
[117]
Löhr JM, Haas SL, Bechstein W-O, et al. Cationic liposomal paclitaxel plus gemcitabine or gemcitabine alone in patients with advanced pancreatic cancer: A randomized controlled phase II trial. Ann Oncol 2012; 23(5): 1214-22.
[http://dx.doi.org/10.1093/annonc/mdr379] [PMID: 21896540]
[118]
Perche F, Torchilin VP. Recent trends in multifunctional liposomal nanocarriers for enhanced tumor targeting. J Drug Deliv 2013; 2013: e705265. Available from: https://www.hindawi.com/journals/jdd/2013/705265/ [Cited 2020 Dec 20].
[119]
Belfiore L, Saunders DN, Ranson M, Thurecht KJ, Storm G, Vine KL. Towards clinical translation of ligand-functionalized liposomes in targeted cancer therapy: Challenges and opportunities. J Control Release 2018; 277: 1-13.
[http://dx.doi.org/10.1016/j.jconrel.2018.02.040] [PMID: 29501721]
[120]
Yi H-G, Choi Y-J, Kang KS, et al. A 3D-printed local drug delivery patch for pancreatic cancer growth suppression. J Control Release 2016; 238: 231-41.
[http://dx.doi.org/10.1016/j.jconrel.2016.06.015] [PMID: 27288878]
[121]
Kalaydina R-V, Bajwa K, Qorri B, Decarlo A, Szewczuk MR. Recent advances in “smart” delivery systems for extended drug release in cancer therapy. Int J Nanomedicine 2018; 13: 4727-45.
[http://dx.doi.org/10.2147/IJN.S168053] [PMID: 30154657]

Rights & Permissions Print Export Cite as
© 2022 Bentham Science Publishers | Privacy Policy